OVID - Stoke Therapeutics Files Proposed Terms For IPO
Quick Take
Stoke Therapeutics (STOK) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing therapeutics for severe genetic diseases with a focus on dominant loss-of-function [haploinsufficient] diseases of the central nervous system, eyes, liver, and kidneys.
STOK has no investor support for the IPO and is still extremely early-stage. The IPO is probably more suited to institutional, long time-frame investors.
Company & Technology
Bedford, Massachusetts-based Stoke Therapeutics was founded in 2014 to develop antisense oligonucleotides [ASOs] that targets